Potravitug - Memo Therapeutics
Alternative Names: Anti-BK polyomavirus (AntiBKV); AntiBKV; AntiBKV - Memo Therapeutics; BK virus-neutralizing antibody - Memo Therapeutics; mAb-319C07; MTX-005Latest Information Update: 28 Aug 2025
At a glance
- Originator Memo Therapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus attachment inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Polyomavirus infections
Most Recent Events
- 19 Aug 2025 Adverse events data from the phase I SAFE KIDNEY I in Polyomavirus infections released by Memo Therapeutics
- 19 Aug 2025 Memo Therapeutics plans to initiate phase III trial for Polyomavirus infections, in 2026 (Memo Therapeutics communication, October 2024)
- 25 Jul 2025 Memo Therapeutics plans to engage with the regulatory authorities to discuss trial design, in late 2025